Shanghai Unicar-Therapy Bio-medicine Technology Co.Ltd
CD30+ CAR T-cells(Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd)은 CD30 표적 세포·유전자 치료로, Relapsed or Refractory Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: of CD30 CAR-T cells, their function in the real-world therapy of r/rHL, and the influence of different treatment regimens on treatment results. Phase 1 안전성·PK 탐색 단계입니다. Background: * Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, . 차별점: unique challenges of successful immunotherapy actualisation in these diseases.
CD30
Relapsed or Refractory Lymphoma
Recruiting
CAR-T cells in combination with anti-PD-1 camrelizumab in relapse
vedotin (BV), a CD30-directed antibody-drug con
linker coupled to h-HFn further improves cellular transport and targeting
unique challenges of successful immunotherapy actualisation in these diseases
of CD30 CAR-T cells, their function in the real-world therapy of r/rHL, and the influence of different treatment regimens on treatment results
Cytokine release syndrome occurred in eight patients (66
apoptosis
CD19 CAR T-cells produce high
escape, could potentially further optimise therapy
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Shanghai Unicar-Therapy Bio-medicine Technology Co.Ltd
CD30+ CAR T-cells(Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd)은 CD30 표적 세포·유전자 치료로, Relapsed or Refractory Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: of CD30 CAR-T cells, their function in the real-world therapy of r/rHL, and the influence of different treatment regimens on treatment results. Phase 1 안전성·PK 탐색 단계입니다. Background: * Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, . 차별점: unique challenges of successful immunotherapy actualisation in these diseases.
CD30
Relapsed or Refractory Lymphoma
Recruiting
CAR-T cells in combination with anti-PD-1 camrelizumab in relapse
vedotin (BV), a CD30-directed antibody-drug con
linker coupled to h-HFn further improves cellular transport and targeting
unique challenges of successful immunotherapy actualisation in these diseases
of CD30 CAR-T cells, their function in the real-world therapy of r/rHL, and the influence of different treatment regimens on treatment results
Cytokine release syndrome occurred in eight patients (66
apoptosis
CD19 CAR T-cells produce high
escape, could potentially further optimise therapy
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.